Chen Bihua
SEC CIK 1599214 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| BLSM | BlossomHill Therapeutics, Inc. | Dir, 10% | 3.30M | $5.00M | — | 2 | 2026-08-10 | 2026-08-10 |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | Dir, 10% | 6.08M | $24.00M | — | 6 | 2024-02-13 | 2026-07-01 |
| HLXC | Helix Acquisition Corp. III | COB, CEO, Dir, 10% | 800.0K | $8.00M | — | 2 | 2026-01-26 | 2026-01-26 |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 10% | 2.34M | $32.44M | $344.1K | 3 | 2024-01-26 | 2025-12-11 |
| AARD | Aardvark Therapeutics, Inc. | Former 10% Owner | 987.7K | $3.00M | — | 2 | 2025-02-14 | 2025-02-14 |
| BIOA | BioAge Labs, Inc. | Former 10% Owner | 1.63M | $8.10M | — | 2 | 2024-09-27 | 2024-09-27 |
| MLTX | MoonLake Immunotherapeutics | 10% | 4.93M | $105.81M | — | 5 | 2022-04-05 | 2023-06-30 |
| TYRA | Tyra Biosciences, Inc. | Dir, Former 10% Owner | 1.07M | $5.00M | — | 2 | 2021-09-17 | 2021-09-17 |
| ERAS | Erasca, Inc. | Dir | 10.51M | $4.42M | $3.75M | 2 | 2021-07-26 | 2021-08-10 |
Most active insiders at BLSM, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | GORDON CARL L | Dir | $10.00M | — |
| 2 | ORBIMED ADVISORS LLC | Dir | $10.00M | — |
| 3 | Chen Bihua | Dir, 10% | $5.00M | — |
| 4 | Schmid John P. | Dir | $96.0K | — |
| 5 | Liptak Vincent Paul | GC | $74.7K | — |
| 6 | Keyes Jason A | CFO | $11.2K | — |
| 7 | Agrawal Sundeep | Dir | — | — |
| 8 | Cui Jingrong Jean | Pres, CEO, Dir, 10% | — | — |
| 9 | Li Yishan | Executive COB, Dir, 10% | — | — |
Transactions 26
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2026-08-10 18:32 | 2026-08-10 | BLSM | BlossomHill Therapeutics, Inc. | Chen Bihua | Dir, 10% | C - Cnv Deriv | — | +3.30M | 3.30M | New | — |
| DI | 2026-08-10 18:32 | 2026-08-10 | BLSM | BlossomHill Therapeutics, Inc. | Chen Bihua | Dir, 10% | P - Purchase | $16.00 | +312.5K | 3.61M | +9% | +$5.00M |
| MI | 2026-07-06 16:34 | 2026-07-01 | BBOT | BridgeBio Oncology Therapeutics, Inc. | Chen Bihua | Dir, 10% | J - Other | $0.00 | 0 | 6.08M | New | $0 |
| DAI | 2026-01-28 | 2026-01-26 | HLXC | Helix Acquisition Corp. III | Chen Bihua | COB, CEO, Dir, 10% | P - Purchase | $10.00 | +800.0K | 800.0K | New | +$8.00M |
| DAI | 2026-01-28 | 2026-01-26 | HLXC | Helix Acquisition Corp. III | Chen Bihua | COB, CEO, Dir, 10% | A - Grant | $10.00 | +497.5K | 497.5K | New | +$4.97M |
| I | 2025-12-15 | 2025-12-11 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Chen Bihua | 10% | S - Sale | $11.46 | -30.0K | 2.34M | -1% | -$344.1K |
| DI | 2025-08-13 | 2025-08-11 | BBOT | BridgeBio Oncology Therapeutics, Inc. | Chen Bihua | Dir, 10% | D - Sale to Iss | $0.00 | -152.9K | 4.53M | -3% | $0 |
| DI | 2025-08-13 | 2025-08-11 | BBOT | BridgeBio Oncology Therapeutics, Inc. | Chen Bihua | Dir, 10% | M - OptEx | — | +4.17M | 4.68M | +820% | — |
| DMI | 2025-08-13 | 2025-08-11 | BBOT | BridgeBio Oncology Therapeutics, Inc. | Chen Bihua | Dir, 10% | A - Grant | $10.72 | +10.95M | 1.54M | New | +$117.39M |
| DI | 2025-02-19 | 2025-02-14 | AARD | Aardvark Therapeutics, Inc. | Chen Bihua | Former 10% Owner | P - Purchase | $16.00 | +187.5K | 987.7K | +23% | +$3.00M |
| DI | 2025-02-19 | 2025-02-14 | AARD | Aardvark Therapeutics, Inc. | Chen Bihua | Former 10% Owner | C - Cnv Deriv | — | +800.2K | 800.2K | New | — |
| DI | 2024-10-01 | 2024-09-27 | BIOA | BioAge Labs, Inc. | Chen Bihua | Former 10% Owner | P - Purchase | $18.00 | +450.0K | 1.63M | +38% | +$8.10M |
| DI | 2024-10-01 | 2024-09-27 | BIOA | BioAge Labs, Inc. | Chen Bihua | Former 10% Owner | C - Cnv Deriv | — | +1.18M | 1.18M | New | — |
| MI | 2024-03-11 | 2024-03-07+ | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Chen Bihua | 10% | P - Purchase | $42.41 | +550.0K | 1.75M | +46% | +$23.33M |
| I | 2024-02-13 | 2024-02-13 | BBOT | BridgeBio Oncology Therapeutics, Inc. | Chen Bihua | CEO, COB, Dir, 10% | A - Grant | $10.00 | +509.0K | 509.0K | New | +$5.09M |
| MI | 2024-02-13 | 2024-02-13 | BBOT | BridgeBio Oncology Therapeutics, Inc. | Chen Bihua | CEO, COB, Dir, 10% | P - Purchase | $10.00 | +2.40M | 903.6K | New | +$24.00M |
| MI | 2024-01-30 | 2024-01-26 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Chen Bihua | 10% | P - Purchase | $32.24 | +282.6K | 678.0K | +71% | +$9.11M |
| I | 2023-07-05 | 2023-06-30 | MLTX | MoonLake Immunotherapeutics | Chen Bihua | 10% | P - Purchase | $50.00 | +800.0K | 4.93M | +19% | +$40.00M |
| MI | 2023-06-28 | 2023-06-26 | MLTX | MoonLake Immunotherapeutics | Chen Bihua | 10% | P - Purchase | $45.63 | +450.0K | 4.10M | +12% | +$20.54M |
| MI | 2023-03-22 | 2023-03-20+ | MLTX | MoonLake Immunotherapeutics | Chen Bihua | 10% | P - Purchase | $20.28 | +827.1K | 3.30M | +33% | +$16.77M |
| DI | 2022-04-07 | 2022-04-05 | MLTX | MoonLake Immunotherapeutics | Chen Bihua | 10% | P - Purchase | $10.00 | +2.85M | 2.85M | New | +$28.50M |
| DI | 2022-04-07 | 2022-04-05 | MLTX | MoonLake Immunotherapeutics | Chen Bihua | 10% | C - Cnv Deriv | $0.00 | +2.79M | 3.21M | +648% | $0 |
| DI | 2021-09-21 | 2021-09-17 | TYRA | Tyra Biosciences, Inc. | Chen Bihua | Dir, Former 10% Owner | P - Purchase | $16.00 | +312.5K | 1.07M | +41% | +$5.00M |
| DI | 2021-09-21 | 2021-09-17 | TYRA | Tyra Biosciences, Inc. | Chen Bihua | Dir, Former 10% Owner | C - Cnv Deriv | — | +757.4K | 757.4K | New | — |
| I | 2021-08-10 | 2021-08-10 | ERAS | Erasca, Inc. | Chen Bihua | Dir | P - Purchase | $22.10 | +200.0K | 10.51M | +2% | +$4.42M |
| I | 2021-08-10 | 2021-07-26 | ERAS | Erasca, Inc. | Chen Bihua | Dir | S - Sale | $18.77 | -200.0K | 10.31M | -2% | -$3.75M |
Purchase Sale Sale after option exercise All abbreviations